Merger Announced
Werewolf Therapeutics and Ambros Therapeutics merger
US$500m equity value
Announced 21 Aug 2026
Advisers
Other advisers
- Legal adviser
- Target
- Ambros Therapeutics
- Acquirer
- Werewolf Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Rare Disease
In the league tables
Similar deals
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
Sources
- 21 Aug 2026 Press release (EX-99.1, exhibit), Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed sec.gov
- 21 Aug 2026 Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private Placement sidley.com
- 21 Aug 2026 Cooley Advised Ambros Therapeutics on $550 Million Merger With Werewolf Therapeutics, Concurrent $150 Million Private Financing cooley.com
